Astellas Pharma was born after Japanese pharmaceutical firms Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical Company merged in 2005, creating one of the largest pharmaceutical companies in Japan. Main products include gastritis treatment Gaster, hypertension therapy Micardis, urology treatment Vesicare, organ transplant immunosuppressant Prograf, and cholesterol drug Lipitor (sold in Japan via an agreement with Pfizer). Astellas' products (including those under development) include cardiovascular, central nervous system, oncology, diabetes, infectious disease, inflammation/immunology, gastroenterology, and urology therapies.

Abbott Nutrition company manufactures and markets nutritional products and devices for customers big and small. A long-held division of Abbott Laboratories, over the years, it has acquired a portfolio of brands that serve multiple niches of the nutritional supplement market. Its infant items include Isomil, PediaSure, Pedialyte, and Similac. In addition, Abbott Nutrition makes adult and diabetic products under brand names such as Ensure, Glucerna, ProSure, and TwoCal. The company also boasts a lengthy list of enteral (feeding) products.

Ortho-McNeil, a subsidiary of gigantic healthcare company Johnson & Johnson, makes a variety of women's health and contraceptive products. A division of Ortho-McNeil-Janssen Pharmaceuticals, its women's health line is dominated by oral contraceptives, including Ortho-cyclen, Ortho-novum, and Modicon; other products include Ditropan for overactive bladder treatment and yeast infection drug Terazol. Sister company Ortho-McNeil Neurologics was created to hold Ortho-McNeil's central nervous system drugs, including epilepsy treatment Topamax, pain management drug Ultracet, Alzheimer's treatments, and migraine remedies, allowing the company to focus strictly on women's health.

Affymax, Inc. company was founded in 2001 and is based in Palo Alto, California. Affymax, Inc., a biopharmaceutical company, engages in the development of peptide-based drug candidates to enhance the treatment of serious and life-threatening conditions. The company’s lead product candidate, Hematide, is designed to treat anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood cells. It is conducting Phase III clinical trials for the treatment of anemia associated with chronic renal failure, on dialysis, and pre-dialysis. Affymax has a license, manufacturing, and supply agreement with Nektar Therapeutics AL, Corporation to manufacture, develop, and commercialize Hematide.

Takeda Cambridge (formerly Paradigm Therapeutics) is researching hundreds of potential drug targets in hopes of finding more effective and faster treatments for central nervous system disorders, endocrinology, urology, chronic pain, and metabolic diseases. The genomics-based drug discovery company, which was spun out of the University of Cambridge, uses several research methods based on genetic models and pharmacology to identify drug targets. Subsidiary Takeda Singapore Pte Ltd conducts research in Asia. The company was acquired by Takeda Pharmaceutical in 2007.

Richter Gedeon was founded by Gedeon Richter in 1901. Richter Gedeon is less interested with Earth's tremors than it is with rumblings caused by human pain and ailments. Hungary's largest producer of pharmaceuticals, the company makes female hormones, ACE inhibitors, anti-anxiety drugs and OTC pain relievers, anti-inflammatories, and vitamin supplements. It specializes in gynecological, cardiovascular, and central nervous system treatments. Brands include Normodipine, Diroton, Panangin, Cavinton, and Mydeton. Richter has a presence in 30 countries; its products are distributed worldwide through its subsidiaries.

GSK Consumer Healthcare, a unit of druggernaut GlaxoSmithKline, makes and sells a wide range of over-the-counter drugs, oral care products, and nutritionals. Brands and products range from oral care (Aquafresh toothpaste) to dermatology (Zovirax cold sore medication), with all kinds of analgesics (Panadol), gastrointestinal remedies (Tums), and smoking-cessation products (Nicoderm) in between. GSK Consumer Healthcare also makes a variety of vitamins and natural remedies, as well as the weight loss product alli.

Genome Explorations Inc. was founded by Dr. Divyen H. Patel to provide academic and industrial institutes with a 'Complete Solution' for Genotyping, Gene expression and miRNA profiling. Dr. Patel initiated and ran the Affymetrix GeneChip processing core at St. Jude Children's Research Hospital. The finding's from one of the many studies conducted through his core was described in a seminal study on the cover of Cancer Cell (Cancer Cell Vol. 1 133-143 March 2002). The study showed for the first time that microarray technology could be used to enhance diagnosis of pediatric leukemia and could also be used to evaluate prognostic outcome. The extensive experience gained through working with scores of investigators on many varying projects has made Genome Explorations Inc. the number one choice for Investigators worldwide.

NextPharma Technologies, also known as NextPharma San Diego (and sometimes known as Bioserv) provides contract manufacturing services to biotechnology, pharmaceutical, diagnostic, and medical device companies. Its facilities can prepare the small batches of biological drugs and placebos used in clinical trials. It can produce solid, liquid, and semi-solid products, as well as injectable drugs. It also offers clinical trial support services and pharmaceutical logistics services. The company's customers include both small and large multinational health care corporations. NextPharma Technologies is the US subsidiary of the UK's NextPharma Technologies Holding Ltd.

Optimer Pharmaceuticals was founded in 1998 and is based in San Diego, California. Optimer Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing anti-infective products worldwide. The company develops products that treat gastrointestinal infections and related diseases. Its two late-stage anti-infective product candidates include Fidaxomicin, the lead product candidate and an antibiotic that is in second Phase III registration trial for the treatment of clostridium difficile-infections; and Prulifloxacin, a prodrug in the fluoroquinolone class of antibiotics, which completed second Phase III trials for the treatment of infectious diarrhea in travelers. It also develops OP-1068/CEM-101, an antibiotic for the treatment of upper and lower respiratory tract infections; OPT-88, a disease-modifying intra-articular, or within the cavity of a joint, therapy for osteoarthritis; OPT-822, a carbohydrate-based cancer immunotherapy for the treatment of metastatic breast cancer; and an OPopS drug discovery platform. The company has a collaborative research and development, and license agreement with Cempra Pharmaceuticals, Inc. to discover, develop, and commercialize drugs based on macrolide and ketolide compounds.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.